INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Sep 30, 2025. Filed Oct 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 30, 2025

IART$14.53+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Dollars in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Total revenue, net	$402,062	$380,834	$1,200,320	$1,167,881
Costs and expenses:
Cost of goods sold	195,071	180,596	589,565	534,892
Research and development	22,456	27,435	74,181	84,167
Selling, general and administrative	169,046	177,193	530,433	538,463
Intangible asset amortization	3,728	3,760	11,186	17,575
Goodwill impairment charge	—	—	511,365	—
Total costs and expenses	390,301	388,984	1,716,730	1,175,097
Operating income (loss)	11,761	(8,150)	(516,410)	(7,216)
Interest income	4,982	5,049	14,112	15,147
Interest expense	(22,725)	(19,373)	(62,582)	(51,648)
Other (expense) income, net	(842)	2,112	(2,932)	2,939
Loss before income taxes	(6,824)	(20,362)	(567,812)	(40,778)
Benefit for income taxes	(1,420)	(9,667)	(53,042)	(14,399)
Net loss	$(5,404)	$(10,695)	$(514,770)	$(26,379)
Net loss per share
Basic and diluted	$(0.07)	$(0.14)	$(6.72)	$(0.34)
Weighted average common shares outstanding (See Note 13):
Basic and diluted	76,753	76,448	76,637	77,196
Comprehensive loss (See Note 14)	(6,472)	(16,823)	(519,174)	$(36,126)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.